OncoMatch/Clinical Trials/NCT06467097
Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma
Is NCT06467097 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for kidney neoplasm.
To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.
Check if I qualifyExtracted eligibility criteria
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 2,000/μL, neutrophils ≥ 1,000/μL, platelets ≥ 50,000/μL
Liver function
total bilirubin ≤ 3.6 mg/dL; AST ≤ 160 U/L; ALT ≤ 165 U/L
Patients with normal major organ function and bone marrow function meeting specific criteria: WBC ≥ 2,000/μL, neutrophils ≥ 1,000/μL, platelets ≥ 50,000/μL. Patients with total bilirubin > 3.6 mg/dL [excluded]. Patients with AST >160 U/L, ALT > 165 U/L [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify